Literature DB >> 16177056

Cutting edge: activation of the aryl hydrocarbon receptor by 2,3,7,8-tetrachlorodibenzo-p-dioxin generates a population of CD4+ CD25+ cells with characteristics of regulatory T cells.

Castle J Funatake1, Nikki B Marshall, Linda B Steppan, Dan V Mourich, Nancy I Kerkvliet.   

Abstract

Activation of the aryl hydrocarbon receptor (AhR) by its most potent ligand, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), leads to immune suppression in mice. Although the underlying mechanisms responsible for AhR-mediated immune suppression are not known, previous studies have shown that activation of the AhR must occur within the first 3 days of an immune response and that CD4+ T cells are primary targets. Using the B6-into-B6D2F1 model of an acute graft-vs-host response, we show that activation of AhR in donor T cells leads to the generation of a subpopulation of CD4+ T cells that expresses high levels of CD25, along with CD62L(low), CTLA-4, and glucocorticoid-induced TNFR. These donor-derived CD4+ CD25+ cells also display functional characteristics of regulatory T cells in vitro. These findings suggest a novel role for AhR in the induction of regulatory T cells and provide a new perspective on the mechanisms that underlie the profound immune suppression induced by exposure to TCDD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177056     DOI: 10.4049/jimmunol.175.7.4184

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  105 in total

1.  You AhR what you eat?

Authors:  B Paige Lawrence; David H Sherr
Journal:  Nat Immunol       Date:  2012-01-19       Impact factor: 25.606

2.  Dietary Indoles Suppress Delayed-Type Hypersensitivity by Inducing a Switch from Proinflammatory Th17 Cells to Anti-Inflammatory Regulatory T Cells through Regulation of MicroRNA.

Authors:  Narendra P Singh; Udai P Singh; Michael Rouse; Jiajia Zhang; Saurabh Chatterjee; Prakash S Nagarkatti; Mitzi Nagarkatti
Journal:  J Immunol       Date:  2015-12-28       Impact factor: 5.422

3.  Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes.

Authors:  Nancy I Kerkvliet; Linda B Steppan; William Vorachek; Shannon Oda; David Farrer; Carmen P Wong; Duy Pham; Dan V Mourich
Journal:  Immunotherapy       Date:  2009-07       Impact factor: 4.196

4.  Consequences of AhR activation in steady-state dendritic cells.

Authors:  Tom Simones; David M Shepherd
Journal:  Toxicol Sci       Date:  2010-11-19       Impact factor: 4.849

5.  The aryl hydrocarbon receptor affects distinct tissue compartments during ontogeny of the immune system.

Authors:  Jason P Hogaboam; Amanda J Moore; B Paige Lawrence
Journal:  Toxicol Sci       Date:  2007-11-17       Impact factor: 4.849

6.  Ikaros sets the potential for Th17 lineage gene expression through effects on chromatin state in early T cell development.

Authors:  Larry Y Wong; Julianne K Hatfield; Melissa A Brown
Journal:  J Biol Chem       Date:  2013-10-21       Impact factor: 5.157

Review 7.  AHR signaling in the development and function of intestinal immune cells and beyond.

Authors:  Luisa Cervantes-Barragan; Marco Colonna
Journal:  Semin Immunopathol       Date:  2018-06-27       Impact factor: 9.623

8.  Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism.

Authors:  Nam Trung Nguyen; Akihiro Kimura; Taisuke Nakahama; Ichino Chinen; Kazuya Masuda; Keiko Nohara; Yoshiaki Fujii-Kuriyama; Tadamitsu Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

Review 9.  A new cross-talk between the aryl hydrocarbon receptor and RelB, a member of the NF-kappaB family.

Authors:  Christoph F A Vogel; Fumio Matsumura
Journal:  Biochem Pharmacol       Date:  2008-10-08       Impact factor: 5.858

10.  The aryl hydrocarbon receptor is required for optimal resistance to Listeria monocytogenes infection in mice.

Authors:  Lewis Zhichang Shi; Nancy G Faith; Yumi Nakayama; Makulasiddappa Suresh; Howard Steinberg; Charles J Czuprynski
Journal:  J Immunol       Date:  2007-11-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.